We’ve been playing our part in the annual ritual of blogging about voting policy updates from big asset managers. They made very few updates to executive compensation policies – and that trend also held true with voting policies that were published in March. Here are a few (incremental) changes that may apply to your company:
– Fidelity – consistent with policy clarifications that Fidelity isn’t intending to influence control of any portfolio company, Fidelity’s policy that it will vote against compensation committee members if the company hasn’t addressed say-on-pay concerns now refers to “concerns raised by shareholders” instead of “concerns communicated by Fidelity”
– T. Rowe Price – clarifying that T. Rowe has flexibility in deciding to vote against compensation committee members in the event of poor compensation practices or option repricings
– Goldman Sachs Asset Management – eliminated internal pay disparity as a factor in say-on-pay
Check out our “Investor Voting Policies” Practice Area for voting guidelines of other investors and asset managers. We’re blogging on TheCorporporateCounsel.net about changes to policies that are unrelated to executive compensation.
– Liz Dunshee
ESG metrics have been under the microscope for some time now, with investors concerned about “ESG overperformance” and companies setting “softball” goals, causing outsized payouts compared to company financial performance. Now, as Liz shared last week, the use of ESG measures seems to be reversing course with a renewed focus on financial measures.
For anyone still tinkering with proxy disclosures describing the continued use of ESG measures in 2024 plans, WTW recently sought to better understand what investors are looking for when they consider pay proposals at companies that use ESG metrics. While many investors reported that they consider the use of ESG metrics on a case-by-case basis, WTW shared some common pitfalls that were identified by surveyed investors.
– Lack of clear connection to business strategy and value creation. This includes the use of metrics that overly rely on subjective judgment, or the use of ESG metrics that are not clearly defined or do not clearly align with the company’s strategy, competitive strengths or material business risks.
– Use of broad ESG indices or compliance-related metrics. Investors do not favor ESG indices as an incentive metric because they are too broad and lack focus. The use of ESG indices also goes against the overarching theme of business materiality. In addition, investors cautioned against the use of compliance-related metrics, as they consider compliance a baseline expectation of executive performance.
– Too many metrics. Too many metrics over-complicate incentive plans and dilute the impact of individual metrics. This weakens the alignment between pay and performance and makes it less meaningful for incentive plan participants. For similar reasons, investors also cautioned the use of less measurable ESG scorecards with undefined weighting of each scorecard element. Additionally, the optics is that the company is building in flexibility to selectively choose which metrics they would add weight to retrospectively when assessing performance and deciding associated pay outcomes.
– Non-financial metrics weighted more heavily than financial metrics. Investors generally shy away from a prescriptive guideline on a minimum or maximum weighting on ESG metrics. However, they noted that, in principle, a small weighting (e.g., lower than 10%) likely will not impact behaviors. A thoughtful approach to selection will naturally result in more meaningful weighting on each individual metric. There also was consensus among the investors that if ESG or non-financial metrics are weighted more heavily than financial or shareholder return metrics, it will draw closer examination. Some investors also expressed concern about high ESG scores offsetting lackluster financial performance in remuneration outcomes.
– Consistent above-target payout. This may signal a lack of rigor on performance goal setting, especially for qualitative measures that require judgment-based assessment.
– Lack of transparent disclosure. Like disclosures on financial metrics, investors expect transparency in the rationale behind metric selection (both retrospective and prospective), with acknowledgement that market norms vary by region), weighting for each metric and achievement against targets. While some companies may cite commercial sensitivity as an argument to omit disclosure of performance goals, investors are mostly unsympathetic to this argument. They assert that ESG targets are generally far less sensitive than financial targets and, if commercial sensitivity does come into play, companies should still be able to disclose the targets and achievement levels retrospectively, after the performance period concludes. Prospective disclosure of targets is encouraged and should clearly show how short- and long-term incentive targets (which often have a one- to three-year time horizon) connect to longer-term sustainability commitments, such as net-zero goals and their transition pathways.
In terms of institutional investor policies on this topic, unsurprisingly, many are still not looking for companies to incorporate ESG measures, but when they’re used, they want to see alignment, goal rigor and transparency.
– Meredith Ervine
If late 2024 PvP comment letters are any indication, there seems to be confusion about what companies need to say about non-GAAP Company-Selected Measures (and additional PvP measures a company may elect to provide). Under Item 402(v)(2)(vi) of Regulation S-K, non-GAAP Company-Selected Measures will not be subject to Regulation G or Item 10(e) of Regulation S-K but companies must disclose how the number is calculated from the audited financial statements. (This requirement intentionally tracked the requirements related to disclosing target levels that are non-GAAP financial measures in CD&A under Instruction 5 to Item 402(b).)
The confusion might stem from the fact that Instruction 5 is limited to target compensation levels. Regulation S-K CDI 118.08 says the instruction does not extend to non-GAAP financial information that does not relate to the disclosure of target levels, so when non-GAAP measures are disclosed in the proxy for other purposes, those are subject to Reg. G and Item 10(e) requirements. But, per the CDI, the Staff will not object if the company provides the disclosure by prominent cross-reference to a proxy statement annex or pages in the Form 10-K. Many companies do this.
It appears that several companies attempted to comply with the requirement to disclose how their non-GAAP Company-Selected Measure in 2024 proxies is calculated from the audited financial statements by cross-referencing other disclosures — either internally in the proxy or to the Form 10-K. But incorporation by reference to a separate filing (even the 10-K) doesn’t work. Cross-referencing disclosure in another section of the proxy statement — like the disclosure intended to comply with Instruction 5 to Item 402(b) — would comply if that section included the full required explanation of how the Company-Selected Measure is calculated from the audited financial statements.
While that explanation will necessarily be tailored to the company and the measure, here’s an explanation provided to the Staff in a response letter from AdaptHealth Corp. of how a Company-Selected Measure — here, Adjusted EBITDA — is calculated from the audited financial statements:
In the 2024 Proxy Statement, the Company calculated Adjusted EBITDA for each year disclosed on the Pay Versus Performance Table as EBITDA, plus loss on extinguishment of debt, equity-based compensation expense, transaction costs, change in fair value of the warrant liability, goodwill impairment, change in fair value of the contingent consideration common shares liability, litigation settlement expense, and certain other nonrecurring items of expense or income. The Company calculated EBITDA as part of the calculation of Adjusted EBITDA for each year disclosed on the Pay Versus Performance Table as net income (loss) attributable to [the company], plus net income (loss) attributable to noncontrolling interests, interest expense, net, income tax expense (benefit), and depreciation and amortization, including patient equipment depreciation.
– Meredith Ervine